RA,SPA,PSA の患者の単一センター横断分析:処方箋データベースからのデータ
Maurizio Benucci1, Francesca Li Gobbi1, Emanuele Antonio Maria Cassarà1
1Rheumatology Unit, S. Giovanni di Dio Hospital, USL-Toscana-Centro, 50143 Florence, Italy.
Journal of personalized medicine
|August 27, 2025
まとめ
この研究では,リウマチ性関節炎 (RA),脊椎関節炎 (SpA),および疹性関節炎 (PsA) のための実際の生物学的治療処方箋を評価し,ITABIOの推奨が適切な治療選択を導くことを発見しました. リウマチ性関節炎は 特に治療が難しい症例では 治療の失敗が顕著でした
科学分野:
- リウマトロジ
- 免疫学
- 薬理学について
背景:
- イタリアの調整生物学的療法委員会 (ITABIO) は以前,RA,SPA,PSAにおける最適な二次線生物学的治療に関する文献をレビューした.
- 炎症性関節炎の患者の健康状態に対するITABIOの勧告の遵守とその影響を評価するために,実際のデータベースが開発されました.
研究 の 目的:
- RA,SpA,およびPsAにおけるセカンドラインの生物学的治療のためのITABIOの推奨の現実世界の適用を検証する.
- 生物学的処方箋の適切性と患者の健康状態の維持における有効性を評価する.
主な方法:
- RA,SpA,またはPsAを患った616人の患者の遡及分析.
- 患者の人口統計,診断,治療歴 (csDMARDs,bDMARDs,tsDMARDs),併発症 (CVリスク要因,肝疾患,感染症,腫瘍,糖尿病) の評価
- 関節外症状の評価は,関節間肺疾患 (ILD),腸炎,乳首炎,腸内炎,およびリウマチ性因子 (RF) /抗シトルリンペプチド抗体 (ACPA) を含む.
主要な成果:
- SpAでは65. 1%,PsAでは52. 4%,RAでは24. 3%でした.
- モノセラピーは一般的であった (全体で68%). RAでは34. 2%が難治 (D2T) であり,54. 8%が単独治療 (トシリズマブ,ウパダシチニブなど) であった.
- アバタセプトはRF/ ACPA陽性RAおよびILD患者に対して好意的であった. セクキヌマブ,イクセキズマブ,アプレミラストのような特定の治療法は,疾患の特徴と併発性に基づいて,SpaAとPsAに標的を絞った使用を示した.
結論:
- 横断分析は,ITABIOの勧告がRA,SPA,PSAの適切な生物学的処方箋を効果的に導くことを確認しています.
- リウマチ性関節炎,特にD2T-RAは,単独治療とMTXの中止の高い割合で特徴づけられる,最も重要な治療上の課題を提示します.
関連する概念動画
Genome-wide Association Studies-GWAS
14.1K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.1K
Cross-Sectional Research
11.8K
In cross-sectional research, a researcher compares multiple segments of the population at the same time. If they were interested in people's dietary habits, the researcher might directly compare different groups of people by age. Instead of following a group of people for 20 years to see how their dietary habits changed from decade to decade, the researcher would study a group of 20-year-old individuals and compare them to a group of 30-year-old individuals and a group of 40-year-old...
11.8K
Analysis of Population Pharmacokinetic Data
382
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
382
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
57
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
57
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
Rheumatic Heart Disease III: Medical Management
31
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
31


